With improved financial and technical supports, many malaria endemic nations are once again considering a goal of malaria elimination. However, this ambitious goal is met with tremendous technical difficulties especially in regions where Plasmodium vivax is prevalent. Interruption of malaria transmission worldwide has been recognized as one of the greatest challenges in malaria elimination. Vaccines that interrupt malaria transmission are ideally suited to this task. However, the progress in development of transmission blocking vaccines (TBVs) has been very slow. To date, we only have a few TBV immunogens with compelling evidence of transmission blocking activities. For P. vivax, TBV studies lag even behind and only two post-fertilization antigens Pvs25 and Pvs28 have been studied. Therefore, this application targets the serious deficiency of knowledge about pre-fertilization stage antigens in the neglected P. vivax parasite using systematic approaches including antigen discovery in rodent malaria parasites, validation of transmission blocking activities in P. vivax, and development of novel vaccine delivery tools.
We aim to 1) identify new sexual stage antigens and evaluate their transmission blocking potentials in the rodent malaria parasite P. berghei;2) validate known pre-fertilization TBV candidates and newly identified candidates using fresh P. vivax clinical isolates;and 3) improve transmission blocking activities of antigens by expressing the antigens in a baculovirus surface display system and by using a TBV combination strategy targeting both pre- and post-fertilization antigens simultaneously. Results from these comprehensive studies will contribute to increased knowledge about TBV development, which is urgently needed for the ultimate elimination of vivax malaria.
This project seeks to use the rodent malaria parasite as a model for initial screening of new transmission blocking vaccine candidates, which will be further validated in the human malaria parasite Plasmodium vivax. Identification and evaluation of transmission blocking vaccines against vivax malaria parasite are urgently needed for the impending malaria elimination campaigns.
|Wang, Qinghui; Zhao, Zhenjun; Zhang, Xuexing et al. (2016) Naturally Acquired Antibody Responses to Plasmodium vivax and Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) C-Terminal 19 kDa Domains in an Area of Unstable Malaria Transmission in Southeast Asia. PLoS One 11:e0151900|
|Zheng, Wenqi; Kou, Xu; Du, Yunting et al. (2016) Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei. Vaccine 34:2570-8|
|Zheng, Li; Pang, Wei; Qi, Zanmei et al. (2016) Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii. Parasit Vectors 9:433|
|Kou, Xu; Zheng, Wenqi; Du, Feng et al. (2016) Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine. Parasit Vectors 9:190|
|Feng, Hui; Gupta, Bhavna; Wang, Meilian et al. (2015) Genetic diversity of transmission-blocking vaccine candidate Pvs48/45 in Plasmodium vivax populations in China. Parasit Vectors 8:615|
|Zheng, Li; Pan, Yanyan; Feng, Yonghui et al. (2015) L-Arginine supplementation in mice enhances NO production in spleen cells and inhibits Plasmodium yoelii transmission in mosquitoes. Parasit Vectors 8:326|
|He, Xiyue; Yan, Juan; Zhu, Xiaotong et al. (2014) Vitamin D inhibits the occurrence of experimental cerebral malaria in mice by suppressing the host inflammatory response. J Immunol 193:1314-23|
|Wei, Xu; Li, Ying; Sun, Xiaodan et al. (2014) Erythropoietin protects against murine cerebral malaria through actions on host cellular immunity. Infect Immun 82:165-73|